abrdn Life Sciences Investors Q1 2026 Commentary
2026-05-20
·
via All Articles on Seeking Alpha
Summary
- The equity portion of the Abrdn Life Sciences Investors Fund rose (gross of fees) but underperformed its benchmark, the NASDAQ Biotechnology Index.
- U.S. equities were relatively resilient earlier in the quarter but ended it sharply lower.
- The conflict in the Middle East led to airspace closures and the blockage of most oil shipments via the Strait of Hormuz.
- During the quarter, the US Federal Reserve (Fed) kept the federal funds target range at 3.50%–3.75%.
Sakorn Sukkasemsakorn/iStock via Getty Images
Fund performance
The equity portion of the Fund rose (gross of fees) but underperformed its benchmark, the NASDAQ Biotechnology Index. 1
Fulcrum Therapeutics (FULC) detracted after disappointing 'phase 3' results for its lead program in
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。